These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 15126649

  • 1. Improving outcomes in hyperphosphataemia.
    De Broe ME, D'Haese PC, Lanthanum Study Group.
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [Abstract] [Full Text] [Related]

  • 2. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ.
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [Abstract] [Full Text] [Related]

  • 5. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F, Hutchison AJ.
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [Abstract] [Full Text] [Related]

  • 6. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F, Hutchison AJ.
    Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
    [Abstract] [Full Text] [Related]

  • 7. Lanthanum carbonate: a new phosphate binder.
    Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME.
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
    [Abstract] [Full Text] [Related]

  • 8. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME.
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [Abstract] [Full Text] [Related]

  • 9. Lanthanum carbonate.
    Freemont AJ.
    Drugs Today (Barc); 2006 Dec; 42(12):759-70. PubMed ID: 17285149
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM.
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [Abstract] [Full Text] [Related]

  • 11. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB.
    Semin Dial; 2007 Dec; 20(4):329-32. PubMed ID: 17635823
    [Abstract] [Full Text] [Related]

  • 12. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
    Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D'Haese PC.
    J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
    [Abstract] [Full Text] [Related]

  • 13. Lanthanum carbonate.
    Swainston Harrison T, Scott LJ.
    Drugs; 2004 Aug; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D, Donne RL, Hutchison AJ.
    Semin Dial; 2007 Aug; 20(4):325-8. PubMed ID: 17635822
    [Abstract] [Full Text] [Related]

  • 17. Effects of efficient phosphate binding on bone in chronic renal failure rats.
    Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC.
    Ren Fail; 2005 Aug; 27(4):475-84. PubMed ID: 16060138
    [Abstract] [Full Text] [Related]

  • 18. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P, Barnett ME, Finn WF, SPD405-307 Lanthanum Carbonate Study Group.
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [Abstract] [Full Text] [Related]

  • 19. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats.
    Damment SJ, Shen V.
    Clin Nephrol; 2005 Feb; 63(2):127-37. PubMed ID: 15730055
    [Abstract] [Full Text] [Related]

  • 20. Lanthanum carbonate: safety data after 10 years.
    Hutchison AJ, Wilson RJ, Garafola S, Copley JB.
    Nephrology (Carlton); 2016 Dec; 21(12):987-994. PubMed ID: 27479781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.